India’s coronary stent market to grow at 4% CAGR until 2033

The country accounts for approximately 32% of the Asia-Pacific market in 2024.

India’s coronary drug-eluting stent market is projected to witness a compound annual growth rate of 4% until 2033, due to rising coronary artery disease cases and the demand for advanced treatments.

A report by GlobalData revealed that India accounted for approximately 32% of the Asia-Pacific market in 2024.

One key development is the recent approval granted to Indian manufacturer Sahajanand Medical Technologies by the Australian Therapeutic Goods Administration for its flagship drug-eluting stent, Supraflex Cruz.

The stent, approved in over 80 countries, combines the sirolimus drug with a biodegradable polymer for faster healing and a reduced likelihood of restenosis.

“With increasing foreign interest and a developing domestic market, India has the potential to enhance its role in the global medical device industry,” Kanchan Chauhan, medical devices analyst at GlobalData, said.